Abstract:Although impactful scientific advancements have recently been made in cancer therapy, there remains an opportunity for future improvements. Immunotherapy is perhaps one of the most cutting-edge categories of therapies demonstrating potential in the clinical setting. Genetically engineered T cells express chimeric antigen receptors (CARs), which can detect signals expressed by the molecules present on the surface of cancer cells, also called tumor-associated antigens (TAAs). Their effectiveness has been extensively demonstrated in hematological cancers; therefore, these results can establish the groundwork for their applications on a wide range of requirements. However, the application of CAR-T cell technology for solid tumors has several challenges, such as the existence of an immune-suppressing tumor microenvironment and/or inadequate tumor infiltration. Consequently, combining therapies such as CAR-T cell technology with other approaches has been proposed. The effectiveness of combining CAR-T cell with oncolytic virus therapy, with either genetically altered or naturally occurring viruses, to target tumor cells is currently under investigation, with several clinical trials being conducted. This narrative review summarizes the current advancements, opportunities, benefits, and limitations in using each therapy alone and their combination. The use of oncolytic viruses offers an opportunity to address the existing challenges of CAR-T cell therapy, which appear in the process of trying to overcome solid tumors, through the combination of their strengths. Additionally, utilizing oncolytic viruses allows researchers to modify the virus, thus enabling the targeted delivery of specific therapeutic agents within the tumor environment. This, in turn, can potentially enhance the cytotoxic effect and therapeutic potential of CAR-T cell technology on solid malignancies, with impactful results in the clinical setting.

Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy

Oncolytic virus enhanced CAR T cell therapy in killing solid tumors

Combining Oncolytic Viruses with Chimeric Antigen Receptor T Cell Therapy

Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment

Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment

Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction

Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment

Oncolytic Viruses as Reliable Adjuvants in CAR-T Cell Therapy for Solid Tumors

Combining CAR T Cell Therapy and Oncolytic Virotherapy for Pediatric Solid Tumors: A Promising Option

CAR-T cell combination therapy: the next revolution in cancer treatment

Alliance between titans: combination strategies of CAR-T cell therapy and oncolytic virus for the treatment of hematological malignancies

Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies

Oncolytic virus–mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice

Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors

The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies

CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances

Oncolytic virotherapy in cancer treatment: challenges and optimization prospects

The emerging field of oncolytic virus-based cancer immunotherapy

CAR T cells in solid tumors: challenges and opportunities

Enhancing Cancer Immunotherapy: A Novel Approach through the Integration of Oncolytic Virotherapy with CAR-T and NK Cell Therapies

Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)